1. Introduction
===============

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder and impacting 5% to 20% reproductive women.^\[[@R1]\]^ It is a complex syndrome characterized by reproductive and metabolic implications including amenorrhea/oligomenorrhea, hyperandrogenism (including hirsutism), or acne and very often by overweight and obesity.^\[[@R2],[@R3]\]^

The pathogenesis of PCOS has not been fully elucidated. However, it is recognized as one of the multiple etiology diseases and seems to have close association with dysregulated steroid state, endocrine disorder, inflammatory, neuroendocrine disease, etc.^\[[@R4]\]^ The role of environmental factors is also under intensive investigation, and it has been demonstrated that persistent organic pollutants (POPs) are associated with PCOS, especially those could interfere with hormonal action, the so-called endocrine disrupting chemicals.^\[[@R5]--[@R8]\]^

The POPs are a variety of synthetic compounds, most of them are man-made^\[[@R9]\]^ via total synthesis. Many POPs are currently or were in the past used as pesticides, solvents, pharmaceuticals, and industrial chemicals. Since they resist photolytic, chemical, and biological degradation, POPs could hardly be degraded via biological photolytic and/or chemical process. It has been proofed that once released into the environment, POPs remain intact for exceptionally long periods of time, they accumulate in the adipose tissue of living organisms including humans.^\[[@R9],[@R10]\]^

The POPs play an important role in the development of a variety of diseases because they have toxic, carcinogenic, and endocrine-disrupting properties that either mimic or block endogenous hormones and thus disrupt normal hormone homeostasis.^\[[@R11],[@R12]\]^

Till now, POPs are recognized as risk factors in the pathogenesis of breast cancer,^\[[@R13]\]^ prostate cancer,^\[[@R14]\]^ thyroid cancer,^\[[@R15]\]^ obesity, type 2 diabetes,^\[[@R16],[@R17]\]^ and hypertension.^\[[@R18]\]^ It is also demonstrated that POPs can damage reproductive and developmental systems of human being, and are associated with risks of female reproductive disorders such as primary ovarian insufficiency,^\[[@R19],[@R20]\]^ early menopause,^\[[@R21]\]^ younger ages of attaining menarche and early sexual maturation,^\[[@R22],[@R23]\]^ prolonged time to pregnancy,^\[[@R24]\]^ pregnancy loss,^\[[@R25],[@R26]\]^ and PCOS.^\[[@R5]--[@R8]\]^

The POPs is a variety of synthetic compounds, although studies have reported the association between certain types of POPs and the risk of PCOS, the current evidence are inconsistent due to the small sample size of designs and the chemical properties. Therefore, it is of great importance to perform a systematic review and meta-analysis to target high risk POPs, it will facilitate a better understanding of what kind of POPs are involved in the pathogenesis of PCOS and provide suggestions for avoiding exposure in daily behavior.

2. Methods and analysis
=======================

The review team develops the methods for the present systematic review and meta-analysis following the PRISMA statement for preferred reporting items for systematic reviews^\[[@R27]\]^ and meta-analysis protocols and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines.^\[[@R28]\]^

2.1. Eligibility criteria
-------------------------

### 2.1.1. Types of studies

The present systematic review will include published articles if they met all of the following criteria: original observational studies on human participants published; exposure related to POPs; outcome of interest is PCOS; studies reported POPs levels in females with PCOS and healthy controls; studies provided POPs means and standard deviation (SD) or provide enough information to calculate such a measure. We will exclude reviews, meta-analyses, ecological studies, case series, case reports, policy papers, and comments.

### 2.1.2. Types of population

The review will include patients with PCOS diagnosed with revised Rotterdam Criteria 2003,^\[[@R29]\]^ National Institute of Health (NIH) 1990 criteria,^\[[@R30]\]^ or Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society criteria.^\[[@R31]\]^

### 2.1.3. Types of exposures

The exposure of interest will be the POPs including polychlorinated biphenyls, polycyclic aromatic hydrocarbons, *p*,*p*′-dichlorodiphenyldichloroethylene, etc.

### 2.1.4. Types of outcome measures

The primary outcome is to identify types of POPs and their levels in serum of subjects.

2.2. Search strategy
--------------------

The reviewers will conduct a systematic literature search in the following electronic databases: PubMed, Embase, Web of Science, and CNKI without language limitations. The search dates will be set from the inception to June 2019. MeSH words and free words with the following searching strategy will be used: ("persistent organic pollutants" OR "pesticide" OR "polychlorinated biphenyls" OR "dichlorodiphenyltrichloroethane" OR "polycyclic aromatic hydrocarbons") AND ("polycystic ovary syndrome" OR "Stein-Leventhal syndrome" OR "polycystic ovarian syndrome" OR "polycystic ovarian disease"). We will also manually retrieve conference proceedings and academic exchange summaries. The whole process of study selection is summarized as flowchart in Figure [1](#F1){ref-type="fig"}.

![Flowchart of study selection.](medi-98-e16948-g001){#F1}

2.3. Data extraction and management
-----------------------------------

Two independent investigators (YL and MZ) will extract and tabulated all data using a standardized data extraction form. Discrepancies will be resolved via referencing the original article and via group discussions or in consultation with the principal investigator (YW). The following data will be extracted leading author, year of publication, journal, country or region, study design, sample size, diagnostic criteria of PCOS, number of PCOS cases, POPs type, POPs concentrations, relative risks of PCOS comparing various levels of POPs, risk estimate confounders, and main conclusion. Investigators will contact the corresponding author of each included study for further information if any important data are missing.

2.4. Appraisal of quality and risk bias
---------------------------------------

Quality of included studies will be assessed using the Newcastle--Ottawa Scale.^\[[@R32]\]^ The NOS assessment consisted of 3 major categories: selection (1 star for each terms), comparability (up to 2 stars), and exposure (1 star for each terms). The score is positively associated with the quality of the study. Funnel plot will be implemented to detect the risk of publication bias if there are more than 10 studies qualified for analysis. Otherwise, Begg test and Egger test will be used.

2.5. Data synthesis
-------------------

The POPs concentrations will be presented as mean and SD. SD value will be transformed if only standard error or the 95% confidence interval is provided. If only median and range are available, mean and SD will be transformed following previously described forum: Mean ≈ Median; SD ≈ Norm IQR = (P~75~ − P~25~) × 0.7413 (IQR = interquartile range, P~75~ = 75th percentile, P~25~ = 25th percentile).^\[[@R33]\]^

Heterogeneity across enrolled studies will be quantified using the *Q*-statistic and inconsistency index (*I*^2^).^\[[@R34]\]^*I*^2^ \> 50%, heterogeneity will be considered as severe; if *I*^2^ = 25% to 50%, heterogeneity will be considered as moderate, and if *I*^2^ \< 25%, heterogeneity will be considered as low. A random-effects model will be used when it is severe heterogeneity, otherwise, a fixed-effect model will be applied. All analyses will be carried out in STATA software (Version 14.0; Stata Corporation, College Station, TX).

2.6. Ethics and dissemination
-----------------------------

Since this is a systematic review and meta-analysis, ethics approval is not required.

We will report our findings of this systematic review and meta-analysis in a peer-reviewed journal in the future.
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